Theravance Biopharma Inc Aktie News

Theravance Biopharma, Inc. (TBPH) Discusses Ampreloxetine Phase 3 Program and Unmet Need in Neurogenic Orthostatic Hypotension with Multiple System Atrophy Transcript

DUBLIN , Nov. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:30 AM ET. To register, click here.

DUBLIN , Nov. 19, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate in the following investor conferences in December 2025: 8th Annual Evercore Healthcare Conference Location: Coral Gables, FL Format: Fireside ChatDate: Thursday, December 4, 2025 Time: 8:20-8:40 AM ET Webcast Oppenheimer Movers in Rare Disease Summit Location: New Yo...

Yupelri's strength helped Theravance achieve non-GAAP profitability this quarter. The company is on track for lucrative milestones.

Theravance Biopharma, Inc. ( TBPH ) Q3 2025 Earnings Call November 10, 2025 5:00 PM EST Company Participants Rick Winningham - CEO & Director Rhonda Farnum - Chief Business Officer and Senior VP of Commercial & Medical Affairs Aine Miller - Senior VP of Development & Head of Ireland Office Aziz Sawaf - Senior VP & CFO Conference Call Participants Douglas Tsao - H.C. Wainwright & Co, LLC, Resear...

YUPELRI® net sales reached an all-time high of $71.4 million, recognized by Viatris, up 15% year-over-year 1 , and achieved record brand profitability Open-label portion of the pivotal Phase 3 CYPRESS study of ampreloxetine now complete; topline readout on track for Q1 2026 Company to host an ampreloxetine focused virtual Key Opinion Leader (KOL) event for investors on December 8, 2025 TRELEGY ...

Ampreloxetine clinical development program to be featured in four presentations at the upcoming International Symposium on The Autonomic Nervous System Topline results from the ongoing Phase 3 CYPRESS study of ampreloxetine anticipated in Q1 2026 DUBLIN , Oct. 29, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will be participating at the 36th Internation...

DUBLIN , Oct. 27, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2025 financial results and provide a business update after market close on Monday, November 10, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST / 10:00 pm GMT) that day.